Safety of abciximab during percutaneous coronary intervention in patients with chronic renal insufficiency.
Jeremias
Allen
A
Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.
Bhatt
Deepak L
DL
Chew
Derek P
DP
Ziada
Khaled M
KM
Albirini
Abdulhay
A
Brener
Sorin J
SJ
Lincoff
A Michael
AM
Topol
Eric J
EJ
Ellis
Stephen G
SG
D000077284:Abciximab; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000925:Anticoagulants / Q000627:therapeutic use*; D006348:Cardiac Surgical Procedures; D003324:Coronary Artery Disease / Q000150:complications* / Q000401:mortality / Q000601:surgery*; D004341:Drug Evaluation; D005260:Female; D005500:Follow-Up Studies; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use*; D015994:Incidence; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009820:Ohio / Q000453:epidemiology; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000627:therapeutic use; D019106:Postoperative Hemorrhage / Q000209:etiology; D012307:Risk Factors; D013921:Thrombocytopenia / Q000209:etiology; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D000925:Anticoagulants; D006454:Hemoglobins; D007140:Immunoglobulin Fab Fragments; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D000077284:Abciximab